Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses current and emerging immunotherapeutic strategies in melanoma.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More